Lncrna ANGPTL1-3 and its target microRNA-30a exhibit potency as biomarkers for bortezomib response and prognosis in multiple myeloma patients

References

• Ruzafa JC, Merinopoulou E, Baggaley RF, et al. Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model. Pharmacoepidemiol Drug Saf. 2016;25(8):871–879.
   PubMed Web of Science ®Google Scholar
• Padala SA, Barsouk A, Barsouk A, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel). 2021;9(1):3.
   PubMedGoogle Scholar
• Albagoush SA, Azevedo AM. Multiple myeloma. Treasure Island (FL): StatPearls; 2021.
   Google Scholar
• Goldman-Mazur S, Kumar SK. Current approaches to management of high-risk multiple myeloma. Am J Hematol. 2021;96(7):854–871.
   PubMed Web of Science ®Google Scholar
• Terpos E, Mikhael J, Hajek R, et al. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021;11(2):40.
   PubMed Web of Science ®Google Scholar
• Landgren O, Rajkumar SV. New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. Clin Cancer Res. 2016;22(22):5428–5433.
   PubMed Web of Science ®Google Scholar
• Soh KT, Wallace PK. Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: Current paradigm, guidelines, and future applications. Int J Lab Hematol. 2021;43(Suppl 1):43–53.
   PubMedGoogle Scholar
• Hudson QJ, Proestling K, Perricos A, et al. The role of long non-coding RNAs in endometriosis. Int J Mol Sci. 2021;22(21):11425.
   PubMed Web of Science ®Google Scholar
• Ouyang J, Zhong Y, Zhang Y, et al. Long non-coding RNAs are involved in alternative splicing and promote cancer progression. Br J Cancer. 2021;126(8):1113–1124.
   PubMed Web of Science ®Google Scholar
• Yao J, Du Y, Liu J, et al. Hypoxia related long non-coding RNAs in ischemic stroke. Noncoding RNA Res. 2021;6(4):153–158.
   PubMed Web of Science ®Google Scholar
• Correia CCM, Rodrigues LF, de Avila Pelozin BR, et al. Long non-coding RNAs in cardiovascular diseases: potential function as biomarkers and therapeutic targets of exercise training. Noncoding RNA. 2021;7(4):65.
   PubMed Web of Science ®Google Scholar
• Wu L, Xia L, Jiang H, et al. Long noncoding RNA DANCR represses the viability, migration and invasion of multiple myeloma cells by sponging miR135b5p to target KLF9. Mol Med Rep. 2021;24(3):649.
   PubMed Web of Science ®Google Scholar
• Liu H, Chi Z, Jin H, et al. MicroRNA miR-188-5p as a mediator of long non-coding RNA MALAT1 regulates cell proliferation and apoptosis in multiple myeloma. Bioengineered. 2021;12(1):1611–1626.
   PubMed Web of Science ®Google Scholar
• Wu L, Xia L, Chen X, et al. Long non-coding RNA LINC01003 suppresses the development of multiple myeloma by targeting miR-33a-5p/PIM1 axis. Leuk Res. 2021;106:106565.
   PubMed Web of Science ®Google Scholar
• Nian F, Zhu J, Chang H. Long non-coding RNA ANGPTL1-3 promotes multiple myeloma bortezomib resistance by sponging miR-30a-3p to activate c-Maf expression. Biochem Biophys Res Commun. 2019;514(4):1140–1146.
   PubMed Web of Science ®Google Scholar
• Khalil NA, Desouky MN, Diab IH, et al. Microrna 30a mediated autophagy and imatinib response in Egyptian chronic myeloid leukemia patients. Indian J Hematol Blood Transfus. 2020;36(3):491–497.
   PubMed Web of Science ®Google Scholar
• Yu Y, Yang L, Zhao M, et al. Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. Leukemia. 2012;26(8):1752–1760.
   PubMed Web of Science ®Google Scholar
• Prieto-Dominguez N, Ordonez R, Fernandez A, et al. Modulation of autophagy by sorafenib: effects on treatment response. Front Pharmacol. 2016;7:151.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Miguel JS, Dimopoulos MA, et al. International myeloma working group recommendations for global myeloma care. Leukemia. 2014;28(5):981–992.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691–4695.
   PubMed Web of Science ®Google Scholar
• Heider M, Nickel K, Hogner M, et al. Multiple myeloma: molecular pathogenesis and disease evolution. Oncol Res Treat. 2021;44(12):672–681.
   PubMed Web of Science ®Google Scholar
• Podar K, Leleu X. Relapsed/refractory multiple myeloma in 2020/2021 and beyond. Cancers (Basel). 2021;13(20)5154.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Nishiwaki K, Yano S. Treatment strategy for multiple myeloma to improve immunological environment and maintain MRD negativity. Cancers (Basel). 2021;13(19):4867.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Otero P, Paiva B, San-Miguel JF. Roadmap to cure multiple myeloma. Cancer Treat Rev. 2021;100:102284.
   PubMed Web of Science ®Google Scholar
• Liu Z, Han M, Meng N, et al. Lncrna MSTRG.29039.1 promotes proliferation by sponging hsa-miR-12119 via JAK2/STAT3 pathway in multiple myeloma. Oxid Med Cell Longev. 2021;2021:9969449.
   PubMed Web of Science ®Google Scholar
• Yang LH, Du P, Liu W, et al. Lncrna ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN. Neoplasma. 2021;68(4):788–797.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao D, Li S, et al. Long non-coding RNA TUG1 knockdown hinders the tumorigenesis of multiple myeloma by regulating the microRNA-34a-5p/NOTCH1 signaling pathway. Open Life Sci. 2020;15(1):284–295.
   PubMed Web of Science ®Google Scholar
• Zhao P, Zhao X. Baseline lncRNA PCAT1 high expression and its longitude increment during induction therapy predict worse prognosis in multiple myeloma patients. J Clin Lab Anal. 2021;35(11):e23924.
   PubMed Web of Science ®Google Scholar
• Ding T, Deng R, Huang T. Long non-coding RNA T cell factor 7 is associated with increased disease risk and poor prognosis, and promotes cell proliferation, attenuates cell apoptosis and miR-200c expression in multiple myeloma. Oncol Lett. 2020;21(2):129.
   PubMed Web of Science ®Google Scholar
• Xu M, Gao WW, Luo YJ, et al. Overexpression of miR-30a promotes apoptosis of leukemia K562 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019;27(2):396-402.
   PubMedGoogle Scholar